266 related articles for article (PubMed ID: 26195207)
1. Novel Ammonia-Lowering Agents for Hepatic Encephalopathy.
Rahimi RS; Rockey DC
Clin Liver Dis; 2015 Aug; 19(3):539-49. PubMed ID: 26195207
[TBL] [Abstract][Full Text] [Related]
2. Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis.
Zacharias HD; Zacharias AP; Gluud LL; Morgan MY
Cochrane Database Syst Rev; 2019 Jun; 6(6):CD012334. PubMed ID: 31204790
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Overt Hepatic Encephalopathy.
Sussman NL
Clin Liver Dis; 2015 Aug; 19(3):551-63. PubMed ID: 26195208
[TBL] [Abstract][Full Text] [Related]
4. Hepatic Encephalopathy: Pharmacological Therapies Targeting Ammonia.
Rahimi RS; Rockey DC
Semin Liver Dis; 2016 Feb; 36(1):48-55. PubMed ID: 26870932
[TBL] [Abstract][Full Text] [Related]
5. Novel Therapies in Hepatic Encephalopathy.
Alimirah M; Sadiq O; Gordon SC
Clin Liver Dis; 2020 May; 24(2):303-315. PubMed ID: 32245535
[TBL] [Abstract][Full Text] [Related]
6. Updates on the pathophysiology and therapeutic targets for hepatic encephalopathy.
Alsahhar JS; Rahimi RS
Curr Opin Gastroenterol; 2019 May; 35(3):145-154. PubMed ID: 30893082
[TBL] [Abstract][Full Text] [Related]
7. Treating hepatic encephalopathy in cirrhotic patients admitted to ICU with sodium phenylbutyrate: a preliminary study.
Weiss N; Tripon S; Lodey M; Guiller E; Junot H; Monneret D; Mayaux J; Brisson H; Mallet M; Rudler M; Imbert-Bismut F; Thabut D;
Fundam Clin Pharmacol; 2018 Apr; 32(2):209-215. PubMed ID: 29239015
[TBL] [Abstract][Full Text] [Related]
8. Treatment of hyperammonemia in liver failure.
Jover-Cobos M; Khetan V; Jalan R
Curr Opin Clin Nutr Metab Care; 2014 Jan; 17(1):105-10. PubMed ID: 24281376
[TBL] [Abstract][Full Text] [Related]
9. Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy.
Rockey DC; Vierling JM; Mantry P; Ghabril M; Brown RS; Alexeeva O; Zupanets IA; Grinevich V; Baranovsky A; Dudar L; Fadieienko G; Kharchenko N; Klaryts'ka I; Morozov V; Grewal P; McCashland T; Reddy KG; Reddy KR; Syplyviy V; Bass NM; Dickinson K; Norris C; Coakley D; Mokhtarani M; Scharschmidt BF;
Hepatology; 2014 Mar; 59(3):1073-83. PubMed ID: 23847109
[TBL] [Abstract][Full Text] [Related]
10. Lactulose vs polyethylene glycol 3350--electrolyte solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial.
Rahimi RS; Singal AG; Cuthbert JA; Rockey DC
JAMA Intern Med; 2014 Nov; 174(11):1727-33. PubMed ID: 25243839
[TBL] [Abstract][Full Text] [Related]
11. Overt Hepatic Encephalopathy: Current Pharmacologic Treatments and Improving Clinical Outcomes.
Rahimi RS; Brown KA; Flamm SL; Brown RS
Am J Med; 2021 Nov; 134(11):1330-1338. PubMed ID: 34242619
[TBL] [Abstract][Full Text] [Related]
12. Ammonia Removal by Metabolic Scavengers for the Prevention and Treatment of Hepatic Encephalopathy in Cirrhosis.
Butterworth RF
Drugs R D; 2021 Jun; 21(2):123-132. PubMed ID: 33890246
[TBL] [Abstract][Full Text] [Related]
13. L-Ornithine phenylacetate (OP): a novel treatment for hyperammonemia and hepatic encephalopathy.
Jalan R; Wright G; Davies NA; Hodges SJ
Med Hypotheses; 2007; 69(5):1064-9. PubMed ID: 17467190
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study.
Kircheis G; Nilius R; Held C; Berndt H; Buchner M; Görtelmeyer R; Hendricks R; Krüger B; Kuklinski B; Meister H; Otto HJ; Rink C; Rösch W; Stauch S
Hepatology; 1997 Jun; 25(6):1351-60. PubMed ID: 9185752
[TBL] [Abstract][Full Text] [Related]
15. Hepatic encephalopathy: a critical current review.
Hadjihambi A; Arias N; Sheikh M; Jalan R
Hepatol Int; 2018 Feb; 12(Suppl 1):135-147. PubMed ID: 28770516
[TBL] [Abstract][Full Text] [Related]
16. Lactulose vs Polyethylene Glycol for Treatment of Hepatic Encephalopathy.
Tapper EB
JAMA Intern Med; 2015 May; 175(5):868. PubMed ID: 25938321
[No Abstract] [Full Text] [Related]
17. Lactulose vs Polyethylene Glycol for Treatment of Hepatic Encephalopathy.
Cutler T; Mints G
JAMA Intern Med; 2015 May; 175(5):867-8. PubMed ID: 25938320
[No Abstract] [Full Text] [Related]
18. Lactulose vs Polyethylene Glycol for Treatment of Hepatic Encephalopathy-Reply.
Rahimi RS; Cuthbert JA; Rockey DC
JAMA Intern Med; 2015 May; 175(5):868-9. PubMed ID: 25938322
[No Abstract] [Full Text] [Related]
19. Serum endotoxin, inflammatory mediators, and magnetic resonance spectroscopy before and after treatment in patients with minimal hepatic encephalopathy.
Jain L; Sharma BC; Srivastava S; Puri SK; Sharma P; Sarin S
J Gastroenterol Hepatol; 2013 Jul; 28(7):1187-93. PubMed ID: 23425082
[TBL] [Abstract][Full Text] [Related]
20. Optimal treatment of hepatic encephalopathy.
Waghray A; Waghray N; Kanna S; Mullen K
Minerva Gastroenterol Dietol; 2014 Mar; 60(1):55-70. PubMed ID: 24632768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
